A Phase III Study of Bevacizumab and Paclitaxel in Combination With Atezolizumab as a Treatment for Locally Advanced Unresectable or Metastatic Hormone Receptor-positive HER2 Negative Breast Cancer

• Status: Recruiting
• Trial end date: 2025-06-30

Summary

JCOG1919E (AMBITION) is a randomized, open-label, phase 3 trial to evaluate efficacy and safety of bevacizumab and paclitaxel in combination with atezolizumab comparing to bevacizumab and paclitaxel in patients with HR-positive HER2 negative metastatic breast cancer.

• Phase: Phase 3

Details

• Lead Sponsor: Japanese Foundation for Cancer Research
• Collaborator: Chugai Pharmaceutical
• Treatments: Albumin-Bound Paclitaxel; Atezolizumab; Bevacizumab; Paclitaxel